泽纳斯生物制药（ZBIO）今日盘前股价大涨6.45%，引起了市场的广泛关注。
消息面上，公司宣布其针对奥贝昔利单抗在免疫球蛋白G4相关疾病治疗中的3期INDIGO注册试验结果，即将在2026年欧洲抗风湿病联盟大会上正式公布。这一关键数据的披露标志着该药物在应对这一复杂自身免疫性疾病方面取得了重要进展，INDIGO试验作为注册性研究，其成果对于评估药物的疗效与安全性至关重要，有望为患者带来新的治疗选择，因此吸引了全球风湿免疫学领域专家与投资者的密切关注。
此次试验结果的公布被视为公司研发管线中的重要里程碑，市场预期积极的数据可能为药物未来的商业化铺平道路，从而推动了股价在盘前交易时段显著上扬。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.